

Technical Report No. 66

Application of Single-Use Systems in Pharmaceutical Manufacturing

2014



PDA Application of Single-Use Systems in Pharmaceutical Manufacturing Technical Report Team

Authors

Robert Repetto, MS, MBA, Team Co-Chair, Pfizer

Morten Munk, Team Co-Chair, CMC Biologics

Stephen Brown, Ph.D., BE Vaccines

Jeffrey Carter, Ph.D., GE Healthcare

Niels Guldager, NNE Pharmaplan

Christian Julien, MS, Meissner Filtration Products, Inc.

Duncan Low, Ph.D., Amgen

Ingrid Markovic, Ph.D., Food and Drug Administration

Jerold Martin, MS, Pall Life Sciences

Paul Priebe, Sartorius Stedim Biotech

Christopher J. Smalley, Ph.D., Merck & Co

Russell Wong, Ph.D., Bayer HealthCare

Contributors

Robin Alonso, Genentech

Eberhard Bill, Ph.D., Boehringer Ingelheim

Oki Dzivenu, GE Healthcare

Bill Hartzel, Catalent Pharma Solutions

Eric Isberg, ATMI

Maik Jornitz, G-Con

Michael Kraich, Ph.D., Boehringer Ingelheim

James Robinson, Lachman Consultants

Hillary Russak, Genentech

Robert Shaw, Finvector—FVT Ltd

Ken Baker, NewAge Industries Inc.

Sally Kline, Ph.D., Amgen

Mani Krishnan, EMD Millipore

Jessica Frantz, Sartorius Stedim Biotech

Disclaimer: The content and views expressed in this technical report are the result of a consensus achieved by the authoring task force and are not necessarily views of the organizations they represent.

Application of Single-Use Systems in Pharmaceutical Manufacturing

Technical Report No. 66

ISBN: 978-0-939459-69-8

© 2014 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 INTRODUCTION	1	4.8 Materials of Construction	23
2.0 GLOSSARY OF TERMS	2	4.8.1 Fluid Management	28
2.1 Acronyms	3	4.8.1.1 Technological Examples	28
3.0 POINTS TO CONSIDER FOR SINGLE-USE SYSTEM MANUFACTURING STRATEGY	4	4.8.2 Mixing	28
3.1 Single-Use Technologies	7	4.8.2.1 Technological Examples	28
3.2 Business Drivers for the Adoption of Single- Use Systems	7	4.8.3 Fermenters and Bioreactors	29
3.3 Qualification and Verification of Suppliers, Materials, Components, and Completed Assemblies	9	4.8.3.1 Technological Examples	29
3.3.1 Product Risk	10	4.9 Storage	30
3.4 Process Control Strategy Considerations	11	4.9.1 Technological Examples	31
3.5 Implementation of a Single-Use System	11	4.10 Freezing	31
3.5.1 Stakeholder Management	11	4.10.1 Technological Examples	31
3.5.2 Risk Management	11	4.11 Filtration	32
3.5.3 Process Validation and Verification (PVV)	12	4.11.1 Technological Examples	32
3.5.4 Scoping	12	4.12 Centrifugation	33
3.5.5 Project Execution Plan (PEP)	12	4.13 Chromatography	33
3.5.6 End-User Requirements	12	4.13.1 Technological Examples	33
3.5.7 Testing and Documentation	12	4.14 Drug Product Final Filling	34
3.5.8 Supplier Management	12	4.14.1 Technological Examples	34
3.5.9 Logistics Control Requirements	12	4.15 Isolators	35
3.5.9.1 Inventory and Supply Chain Management .	13	4.16 Sampling and Laboratory Analysis	36
3.5.9.2 Waste	13	4.16.1 Technological Examples	36
3.5.9.3 Transportation	13	4.17 Transportation	37
3.5.9.4 Single Suppliers	13	4.17.1 Technological Examples	37
3.5.9.5 Change notifications	13	4.18 Sensors	38
3.5.9.6 Technical Diligence	14	4.18.1 Technological Examples	38
3.6 Implementation Summary	14	4.19 System Integration	39
4.0 SINGLE-USE TECHNOLOGIES AND SYSTEM INTEGRATION	15	4.20 Supply Chain Integration	39
4.1 Introduction	15	4.20.1 Factors Which Affect the Quality of Supply Chain	39
4.2 Comparison of MUS and SUS	15	5.0 QUALIFICATION AND VERIFICATION OF SUPPLIERS, MATERIALS, COMPONENTS, AND COMPLETED ASSEMBLIES	40
4.3 SU Components and Assembly	16	5.1 Introduction	40
4.4 Technical Feasibility and Risk Assessment Framework	17	5.2 Risks Associated with Using Single-Use Systems	41
4.5 Factors Affecting SUS Design	18	5.3 Single-Use System Assembly	43
4.5.1 Process Compatibility	18	5.4 Supplier Qualification of Single-use Systems	43
4.6 Facility Impact for SUS Setup and Deployment	20	5.4.1 Supplier Audits and Technical Diligence ..	43
4.6.1 Operational Requirements	20	5.4.2 Supplier Quality Agreements and Responsibilities	44
4.7 Applications and Technology	21	5.5 Qualification of Alternative Suppliers	44
4.7.1 Process Connections	21	5.5.1 Qualification of Alternative Sources	44
4.7.1.1 Technological Examples	21	5.5.2 Interchangeability	45
		5.5.3 Using Supplier Quality Documentation	46
		5.6 Extractables and Leachables (E&L)	47
		5.6.1 Material and Supplier Qualification	48
		5.6.2 Toxicity of E&L	52

5.6.3	Using Supplier Documentation for Extractables.....	52
5.6.4	Extractable Testing Standardization.....	53
5.7	Bovine Spongiform Encephalopathy (BSE)/ Transmissible Spongiform Encephalopathy (TSE) Concerns.....	53
5.8	The Quality Systems of the End User and Supplier.....	53
5.9	Quality Management for Single-Use System Implementation.....	53
5.9.1	Determination of Expiration Date and Shelf Life.....	53
5.9.2	Dealing with Particulates.....	54
5.9.3	Sanitation and Sterilization.....	54
5.9.4	Bioburden Control.....	54
5.10	Sterilization.....	55
5.10.1	Irradiation Sterilization.....	55
5.10.2	Sterilization with Moist Heat.....	55
5.10.3	Sensor Technology.....	56
5.10.4	Qualification and Validation.....	56
5.11	Integrity.....	57
5.11.1	Testing an SUS for Leaks.....	57
5.11.2	Leak Prevention in an SUS.....	58
5.12	Campaigning.....	60

6.0 BUSINESS DRIVERS FOR THE ADOPTION OF SINGLE-USE SYSTEMS..... 61

6.1	Evaluation of Business Drivers.....	61
6.2	Lifecycle Approach.....	61
6.3	Opportunity Cost.....	62
6.4	Cost of Quality.....	62
6.5	Quantitative Evaluation of Business Drivers.....	62
6.5.1	Process Assessment.....	63
6.5.2	Batch Frequency.....	63
6.6	Operational Model.....	64
6.6.1	Single- or Multiple-Product Facility.....	64
6.7	Total Cost Model.....	64
6.7.1	Shortcut Cost Model Based on Cost of Goods.....	65
6.7.2	Example of a Shortcut Cost Model.....	65
6.7.3	Comprehensive Cost-of-Goods Model.....	66
6.8	Investment Costs.....	66
6.8.1	Process Equipment.....	66
6.8.2	Utility Equipment.....	66
6.8.3	Indirect Equipment Costs.....	67
6.8.4	Facility.....	67
6.8.5	Materials.....	67
6.8.6	Consumables.....	67
6.8.7	Utilities.....	68

6.8.8	Waste.....	68
6.9	QC/QA and Cost of Quality.....	68
6.10	Fixed Operating Costs.....	68
6.10.1	Cost of Capital.....	69
6.10.2	Depreciation.....	69
6.10.3	Staff.....	69
6.11	Project Duration, Time, and Productivity.....	70
6.11.1	Overall Project Duration.....	70
6.11.2	Process Operation Time.....	70
6.11.3	Time Constraints.....	70
6.11.4	Speed of Process Development.....	70
6.11.5	Equipment and Process Validation.....	71
6.11.6	Construction Time.....	71
6.11.7	Self-Assembly.....	71
6.12	Logistics.....	71
6.12.1	Supply.....	72
6.12.2	Storage.....	72
6.12.3	Transportation.....	72
6.12.4	Waste.....	72
6.13	Disposal of an SUS.....	73
6.14	Sustainability.....	74
6.15	The Value Added.....	74
6.15.1	Value-Added Analysis.....	75

7.0 IMPLEMENTATION OF A SINGLE-USE SYSTEM.... 77

7.1	Implementation Road Map.....	77
7.2	Implementation Themes.....	80
7.2.1	Stakeholder Management.....	80
7.2.2	Risk Management.....	81
7.2.3	Process Validation and Verification (PVV).....	84
7.3	Implementation S3: Scoping.....	85
7.3.1	SUS Strategy.....	85
7.3.2	Business Drivers.....	85
7.3.3	Operating Scenarios and Standardization.....	86
7.3.4	Process Validation Stage.....	86
7.3.5	Operating Volumes and Storage Requirements.....	86
7.3.6	Hybrid Systems.....	86
7.3.7	Connection Principles.....	86
7.3.8	Campaigning.....	86
7.3.9	Future Deployment.....	86
7.3.10	Sourcing.....	87
7.3.11	Testing Strategy.....	87
7.3.12	Materials.....	87
7.3.13	Shelf-Life Policy.....	87
7.3.14	Procurement.....	87
7.3.15	Storage.....	87
7.3.16	Waste Treatment.....	88
7.3.17	Non-GxP Issues.....	88

7.3.18 Sustainability.....	88	7.6.4 Training	101
7.4 Implementation S4: Business Case.....	88	7.6.5 Training Workflow.....	101
7.4.1 Project Execution Plan	88	7.6.6 An Example of SUS Training	101
7.4.2 Process and Facility Requirements: Basis of Approach	89	7.6.7 Safety	102
7.4.3 Facility-Level Plan	89	7.6.8 Preparation of a Health, Safety, and Environment Plan	102
7.4.4 Implementation-Level Plan.....	90	7.6.9 Health and Safety Issues Related to SUS	102
7.4.5 Operational-Level Plan	90	7.7 Implementation S7: Launch.....	103
7.4.6 Facility-Level Integration Plan	91	7.7.1 Management of Materials.....	103
7.4.7 Equipment-Level Integration Plan.....	93	7.7.2 Routine or Operational Procurement	103
7.4.8 Operational-Level Integration Plan	94	7.7.3 Technical Diligence	104
7.4.9 Technological Survey	94	7.7.4 Quality and Technical Agreements.....	106
7.4.10 Supplier Selection and Supply-Chain Review	95	7.7.5 Logistics and Storage	106
7.4.11 Extractables and Leachables Database...	96	7.7.6 Waste	107
7.5 Implementation S5: Development	96	7.7.7 Post-launch Review	107
7.5.1 User Requirements for Implementation ...	96	8.0 APPENDIX I: OVERALL USER REQUIREMENT SPECIFICATION EXAMPLE	108
7.5.2 Preparing User Requirements	96	9.0 APPENDIX II: PROJECT EXECUTION PLAN EXAMPLE	121
7.5.3 Layout and Design	97	10.0 APPENDIX III: TRAINING REQUIREMENTS EXAMPLE.....	135
7.5.4 Specification	98	11.0 REFERENCES	136
7.5.5 Standardization Policy.....	99		
7.5.6 Extractables and Leachables	99		
7.5.7 Procurement	99		
7.6 Implementation S6: Testing and Validation	100		
7.6.1 Delivery	100		
7.6.2 Installation	100		
7.6.3 Qualification	100		

FIGURES AND TABLES INDEX

Figure 3.0-1	Key Decision Areas for an SUS Manufacturing Strategy.....	4	Table 5.2-1	Risk Complexities of SUS Items and Applications.....	42
Figure 3.0-2	Proposed SUS Decision Pathway	6	Table 5.5.2-1	Component Interchangeability Evaluation	46
Figure 3.0-3	Technical Report Structure Overview....	6	Table 5.5.3-1	Example Supplier Testing and Reference Standards	47
Table 4.2-1	Comparison of MU and SU Systems ..	15	Table 5.6.1-2	Example—Quantitation of Extractables from SU Components after 50 kGy Irradiation	50
Figure 4.3-1	Anatomy of an SUS	16	Table 5.6.1-3	Identified Extractables from Membrane Filter Cartridges from Several Manufacturers	51
Figure 4.4-1	Implementation of an SUS and the Assessment of Drug Process and Product Risk	17	Table 5.6.1-4	Identification of Extractables from Polyethylene Biocontainers with Ethyl Vinyl Alcohol Interlayer	51
Table 4.5.1-1	Assessment of Process Compatibility	19	Figure 5.11.2-1	Investigation of a Bioprocess Container for Leaks	58
Table 4.6-1	Assessment of SUS Facility Setup and Deployment	20	Figure 5.11.2-2	Identifying the Location of Leaks on a Bioprocessing Container.....	59
Table 4.6.1-1	Assessment of Operational Requirements	21	Figure 6.5-1	Cost Comparison Studies Reference Model.....	63
Table 4.7.1.1-1	Functional Categories of Connectors ..	22	Table 6.5-1	Factors That Affect the Process Model ..	63
Table 4.7.1.1-2	Specific Considerations for Connectors	23	Table 6.6-1	Factors That Affect the Operational Model	64
Table 4.8-1	Plastics Commonly Used in SUS	24	Table 6.7-1	Comparative Evaluation of a New Versus Retrofitted Facility During SUS Implementation.....	64
Table 4.8.1.1-1	Specific Considerations for Fluid Management	28	Table 6.8.1-1	Contributory Factors to Investment Costs	66
Table 4.8.2.1-1	Specific Considerations for Mixing	29	Table 6.8.4-1	Main Variable Operating Costs	67
Table 4.8.3.1-1	Specific Considerations for Fermenters or Bioreactors	30	Table 6.10-1	Main Fixed Operating Costs	69
Table 4.9.1-1	Specific Considerations for the Storage of Process Intermediates	31	Table 6.13-1	Treating and Discarding Waste from SUSs	74
Table 4.10.1-1	Specific Considerations for Freezing ..	32	Table 6.15.1-1	Comparison of Value-Added Activities ..	75
Table 4.11.1-1	Specific Considerations for Filtration ..	33	Figure 7.1-1	SUS Implementation Road Map.....	78
Table 4.13.1-1	Specific Considerations for Chromatography	34	Table 7.1-1	Focus and Output for Each SUS Implementation Stage.....	79
Table 4.14.1-1	Specific Considerations for Drug Product Final Filling.....	35	Figure 7.2.1-1	An Example of a Stakeholder Power Grid.....	81
Table 4.15-1	Specific Considerations for Isolators ..	36	Table 7.2.3-1	Guidelines for the Application of Risk Management During SUS Implementation.....	82
Table 4.16.1-1	Specific Considerations for Sampling and Laboratory Analysis	37			
Table 4.17.1-1	Specific Considerations for Transportation.....	38			
Table 4.18.1-1	Specific Considerations for Sensors ...	39			
Figure 4.19-1	System Integration	39			
Figure 5.2-1	Example of an Ishikawa Diagram for Determining Risk Sources	41			

Table 7.2.3-2	Directional Risk Profile of SUS Items and Applications.....	83	Table 7.4.6-1	Example of a Regulatory Assessment Table.....	92
Table 7.2.3-3	Risk Management and Mitigation in Current and Future SUS Implementation.....	83	Figure 7.5.3-1	Example of SUS Installation Scope Drawing.....	97
Figure 7.2.3-1	SUS Implementation and the Validation Lifecycle	84	Table 7.7.3-1	Principle Differences Between a Quality Audit and a Technical Diligence Assessment.....	104
Table 7.4.1-1	Typical Contents of the SUS Project Execution Plan	89	Table 7.7.3-2	Some Pertinent Factors for a Technical Diligence Assessment Checklist.....	105
Figure 7.4.5-1	SUS Process and Facility Integration..	90	Table 7.7.3-3	An Interpretation of the SUS Implementation Process	106
Figure 7.4.6-1	Process and Facility Considerations for SUS Implementation.....	91	Table 8.4.3.1-1	Sample Room Classifications	117

1.0 Introduction

Single-use technology, often described as single-use systems (SUSs) or single-use equipment, has the potential to transform pharmaceutical manufacturing by offering tremendous opportunities to reduce cost, improve flexibility or cycle time, and shorten the time needed to build a manufacturing process for new, lifesaving drugs. This success, however, is very much dependent on how effectively the industry approaches the development and implementation of single-use technology. Ultimately, a new drug can only be successful if it is effective, safe, and available. Traditionally, only a comprehensive understanding of the drug product and manufacturing process can achieve these goals. This remains true as SUS is introduced in place of traditional reusable equipment. Encouraging an open science- and risk-based dialogue during supplier audits and evaluation of SUS supply chains significantly improves an SUS implementation.

This document is intended to provide the reader with critical concepts or points to consider when implementing an SUS strategy in a pharmaceutical manufacturing process. These concepts are intended to be valid both for chemically synthesized small molecules and for bioprocesses that produce large-molecule biopharmaceutical products. However, to be truly effective, many of these critical concepts must start with the design, supply chain, manufacturing, and distribution of SUSs themselves, as many inherent quality attributes can impact either the product molecule or its production process. Pharmaceutical manufacturers and single-use technology suppliers have become partners whose success is dependent on the control strategies implemented.

This document discusses SUSs that are in either direct or indirect contact with the raw materials, intermediates, and pharmaceutical drug substances or drug products. The document does not intend to discuss disposable items related to laboratory activities, final delivery system to the patient, transfusion bags, packaging, or medical devices.

Successful SUS implementation needs a comprehensive approach balancing the product and process goals achieved by using single-use technology. Section 3, Manufacturing Strategy, of this technical report is intended to present an approach that ties together key considerations when evaluating single-use technology. A well-designed manufacturing strategy will address technical, quality, business, and implementation considerations. Each topic has a dedicated section in this technical report, providing a detailed discussion of the associated considerations.

Determining the optimal manufacturing strategy involves concepts from many disciplines. An effective evaluation will have a balanced viewpoint, with input from engineering, regulatory, quality, project management, and accounting. Balancing risks and rewards of an SUS over a multiple-use system (MUS) will help determine the most appropriate manufacturing strategy. Thus, a structured science- and risk-based approach is recommended and should be consistent with principles described in ICH Guidelines Q6, Q7, Q8, Q9, Q10, and Q11. Primary goals, when developing any manufacturing strategy, should focus on controlling impacts to patient safety, product availability, and product and process understanding (1–6).

Only a formal partnership with an SUS supplier can ensure that quality is as good as or better than what is achieved with traditional systems (e.g., a purchase order is not a partnership). SUS suppliers provide equipment that includes the outsourced, value-added activities that the end user no longer performs. These value-added activities are important for the success of both organizations, and a winning control strategy for SUS has elements in both the supplier's and the end user's quality systems.

The concepts and recommendations presented in this technical report were developed over several years of discussion within the task force, at PDA workshops, and at other industry meetings. The authors of this technical report recognize that the conversation regarding how best to implement SUSs is just beginning. Ultimately the success of these systems will be determined by the decisions suppliers and end users make during implementation, and the hope is that this report provides a foundation for the industry to build on.